MedPath

Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia

Completed
Conditions
Cervical Dystonia
Registration Number
NCT02175693
Lead Sponsor
Eisai Co., Ltd.
Brief Summary

Investigation of the clinical condition and safety in patients with cervical dystonia

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1647
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Overall assessments of the improvement in the seriousness of seizuresUp to 3 years

Improvement is based on the 5 following elements: 1) Eminent improvement 2) Improvement 3) Improvement a little invariability 5) Exacerbation 6) It is not possible to judge

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath